Cytokine storm and use of anakinra in a patient with COVID-19
Priyanka Nemchand, Hassan Tahir, Rapti Mediwake, Jeffrey Lee
Abstract
We present a case of a 50-year-old man with COVID-19 infection and acute respiratory distress syndrome as a result of a cytokine storm and use of anakinra, an interleukin 1-receptor antagonist that is normally used in the treatment of autoinflammatory disorders in adult patients. We saw a reduction in oxygen requirement and improvements in inflammatory markers and ferritin. Although we cannot determine its clinical efficacy from one case study, it may have a positive effect on the proinflammatory state that is associated with cytokine storm in COVID-19 infection.
Topics & Concepts
AnakinraCytokine stormMedicineCoronavirus disease 2019 (COVID-19)Proinflammatory cytokineCytokineImmunologyRespiratory distressAcute respiratory distressARDSReceptor antagonistInflammationInternal medicineReceptorAntagonistAnesthesiaLungDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesInflammasome and immune disordersDermatological and COVID-19 studies